Sam­sung BioEpis pitch­es Her­ceptin biosim­i­lar as par­ent com­pa­ny hunts $2B IPO; Chi­as­ma CEO is out

In the lat­est ad­vance by a new wave of biosim­i­lars hit­ting reg­u­la­tors on both sides of the At­lantic, Sam­sung Bioepis says that it has filed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA